



Lysogene Announces Licensing Agreement for LYS-SAF302, a Late-stage Gene Therapy, to Sarepta for the US and Markets Outside of Europe

Torreya Advised Lysogene on Licensing Transaction

Paris, France and Cambridge, MA October 15, 2018

Lysogene, a biopharmaceutical company specializing in gene therapy targeting the central nervous system (CNS), signed a license agreement with Sarepta Therapeutics, Inc., a leader in precision genetic medicine for rare diseases, for the development of LYS-SAF302, a gene therapy to treat Mucopolysaccharidosis type IIIA (MPS IIIA). MPS IIIA is a rare, severe and fatal inherited neurodegenerative lysosomal storage disorder. Sarepta will also have certain option rights to an additional Lysogene CNS-targeted gene therapy candidate.

Lysogene will receive \$15 million (€13m) on closing, with payments in 2018 totaling \$26 million (€22m). Payments from Sarepta to Lysogene for all items, if all milestones are met, would total approximately \$125 million (€108m) plus royalties. As part of the transaction, Sarepta will make an equity investment in Lysogene of \$2.5 million (€2.1m) at a 30% premium. Sarepta receives full commercial rights to LYS-SAF302 in the U.S. and other markets outside of Europe, while Lysogene retains full commercial rights in Europe, and Sarepta will be responsible for manufacture of LYS-SAF302 globally.

Torreya served as the exclusive financial advisor to Lysogene on this transaction.

This transaction reinforces Torreya's strength and leadership position as an advisor to biotechnology companies. Torreya has advised on 20 completed strategic and financing transactions in the life sciences industry thus far in 2018.

ABOUT LYSOGENE

For more information about Lysogene, please see: www.lysogene.com

ABOUT SAREPTA THERAPEUTICS, INC.

For more information about Sarepta, please see: www.sarepta.com

Deal Press Release

Torreya Contact

STEPHANIE LÉOUZON

Partner | London Office

stephanie.leouzon@torreya.com | +44 (0) 207.451.4551 | torreya.com

LYSOGENE
Licensing of ex European rights for LYS-SAF302 to

SAREPTA
THERAPEUTICS

\$15 million upfront
with up to \$110m in additional payments plus royalties
October 2018

Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.